EDITORIAL

Chairmen's introduction

pH-Hp: implications for dyspepsia management

A Axon, N J Talley, S J O Veldhuyzen van Zanten

¹ Centre for Digestive Diseases, General Infirmary at Leeds, Leeds, UK
² Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
³ Division of Gastroenterology, Dalhousie University, Halifax, Nova Scotia, Canada

Correspondence to:
Correspondence to:
Professor A T R Axon, Gastroenterology Unit, General Infirmary, Great George Street, Leeds LS1 3EX, UK;
anthonya@ulth.northy.nhs.uk

---

Introduction to the proceedings of the symposium on dyspepsia management, held in Geneva, Switzerland, December 1998.

---

Keywords: pH; Helicobacter pylori; dyspepsia

Clinical trials using omeprazole began in 1983. Research since then, involving more than 50 000 patients, has shown that this drug is safe and well tolerated. It is consistently effective in the treatment of peptic ulcer disease and gastro-oesophageal reflux disease. It plays a pivotal role in the treatment of Helicobacter pylori infection. It is also valuable in prophylaxis for patients taking non-steroidal anti-inflammatory drugs and in the intensive care unit for stress ulcer prophylaxis. For all of these reasons, omeprazole has become increasingly popular in recent years and today is one of the most widely prescribed drugs in the world.

Although its effectiveness in the management of organic disease is well accepted, omeprazole is also used by doctors in primary and secondary care for patients with non-organic or functional dyspepsia. The indications for its use in this condition however have been relatively under investigated. In this supplement, . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?